title: Recent EORTC and MRC UK studies: implications for imaging ovarian cancer.
abstract: For many years the primary management of newly diagnosed advanced ovarian cancer has been cytoreductive surgery followed by chemotherapy, and the mainstay of follow-up of treated women has been serial assay of serum CA-125. The findings of 2 recent research protocols have a significant effect on these aspects of management.
authors.affiliation: Department of Clinical Radiology, St James's Institute of Oncology, Leeds, LS9 7TF, UK. johnaspencer50@hotmail.com
authors.forename: John A
authors.initials: JA
authors.lastname: Spencer
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Perren
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D018394:CA-125 Antigen / Q000032:analysis; D003952:Diagnostic Imaging; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D011859:Radiography; D016032:Randomized Controlled Trials as Topic; D006113:United Kingdom
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen